IHS Chemical Week

People & Business :: M&A

Mylan to acquire Abbott's non-US branded generics pharma business

1:18 AM MDT | July 18, 2014 | Natasha Alperowicz

Mylan (Pittsburgh) has entered into a definitive agreement with Abbott to acquire Abbott's non-US developed markets specialty and branded generics business in an all-stock transaction. Abbott will receive 105 million shares of the combined company, worth approximately $5.3 billion based on Mylan's closing price of $50.20 on 11 July, representing an approximately 21% ownership stake. The transaction will further diversify Mylan's business and strengthen its commercial platform outside the United States, building new opportunities for growth and additional sales...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa